Volume 30, Number 3—March 2024
Research
Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan
Cheng-Yi Lee, Hung-Wei Kuo
, Yu-Lun Liu, Jen-Hsiang Chuang, and Jih-Haw Chou
, Yu-Lun Liu, Jen-Hsiang Chuang, and Jih-Haw Chou
Table
Vaccination status and outcomes in a population-based evaluation of vaccine effectiveness against SARS-CoV-2 infection, severe illness, and death, Taiwan
| Vaccination status and outcomes | Total population | Unvaccinated | No. doses |
||
|---|---|---|---|---|---|
| 1 | 2 | 3 | |||
| No. (%) cases |
21,416,151 (100) |
3,373,548 (15.8) |
1,183,138 (5.5) |
3,287,659 (15.4) |
13,571,806 (63.4) |
| Mean age (SD) |
39.9 (21.5) |
41.0 (30.6) |
28.7 (25.7) |
31.8 (22.4) |
42.5 (16.8) |
| Sex | |||||
| M | 10,644,720 | 1,720,573 | 644,365 | 1,741,738 | 6,538,044 |
| F |
10,771,431 |
1,652,975 |
538,773 |
1,545,921 |
7,033,762 |
| SARS-CoV-2 infection | |||||
| No. confirmed cases (%) |
5,830,809 (27.2) |
819,991 (24.3) |
371,202 (31.4) |
903,475 (27.5) |
3,736,141 (27.5) |
| COVID-19 prognosis | |||||
| No. moderate and severe cases (%) | 28,840 (0.13) | 14,674 (0.43) | 2,575 (0.22) | 3,700 (0.11) | 7,891 (0.06) |
| No. deaths (%) | 10,667 (0.05) | 5,342 (0.16) | 989 (0.08) | 1,305 (0.04) | 3,031(0.02) |
Page created: February 15, 2024
Page updated: February 22, 2024
Page reviewed: February 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.